The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000800325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/06/2026
Date registered
Help: Date registered
3/07/2026
Date last updated
Help: Date last updated
3/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Does pre-prandial (before meals) compared to prandial (with meals) ingestion of metformin optimise glucose lowering in people with type 2 diabetes?
Scientific title
Does pre-prandial (before meals) compared to prandial (with meals) ingestion of metformin optimise glucose lowering in people with type 2 diabetes?
Additional trial identifiers [1] 317709 0
Nil
Universal Trial Number (UTN)
Trial acronym
OPTIMET(Optimising metformin timing) Trial
Related trial records

Health condition
Health condition(s) studied:
Type 2 diabetes 342392 0
Condition category
Condition code
Metabolic and Endocrine 338516 338516 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Prior to being assigned a randomisation code, participants will undergo a screening visit at the Adelaide University Clinical Research Facility (CRF) within the AHMS Building, to evaluate their eligibility. Prior medical history will be collected via a standardised questionnaire by the study investigators. Individuals will have had prior opportunity to read the Participant Information and to discuss their participation with their family and friends, if they wish. Investigators will explain the study protocol and answer any questions the volunteers may have about what is involved, before the volunteers provide written, informed consent, and 10 mL fasting venous blood will be collected for HbA1c, glucose, and liver and kidney function.

After enrolment, each participant will undergo a 10-day trial in a double-blind, randomised, crossover design, with treatment allocation assigned by the Royal Adelaide Hospital Pharmacy. Metformin and placebo (cellulose) will be encapsulated in identical gelatin capsules and packed by the Royal Adelaide Hospital Investigational Drugs Pharmacy. Only the designated pharmacists at the Royal Adelaide Hospital Investigational Drugs Pharmacy will dispense the study compounds.

The study includes two 3-day treatment periods:
(i) immediate-release metformin 500mg 3 times daily, administered 60 min before breakfast, lunch and dinner, with matched placebo administered with meals; and
(ii) immediate-release metformin 500mg 3 times daily, administered with breakfast, lunch and dinner,
with matched placebo administered 60 min before meals.

On Day 0, participants will attend the CRF, where a continuous glucose monitoring (CGM) sensor (FreeStyle Libre Pro, Abbott, IL, USA) will be fitted by one of the investigators to record glucose levels throughout the study period. Participants will continue their usual metformin regimen on Day 1 to establish baseline glucose profiles.

Between Days 2-4 and Days 8-10, participants will cease their usual metformin regimen and receive one of the two study treatments. Participants will ingest treatments themselves and be reminded by daily text messages. The treatment periods will be separated by a 3-day washout period (Days 5-7), during which participants will resume their usual metformin regimen. The blister pack of the study drug checked at each study day (Days 4 and 10) to monitor adherence to the intervention.

On Days 4 and 10 (the final day of each treatment period), participants will attend a study visit and be provided with 3 standardised test meals. On the evening preceding each visit (~1900h), they will be given a standardised evening meal (frozen beef lasagne, McCain Foods Proprietary Ltd, VIC, Australia; 2472kJ). Following this meal, they will be asked to fast from solids and liquids (water may be consumed until midnight) until the following morning, when they will attend our CRF at ~0800h. Upon arrival, participants will be fitted an ambulatory blood pressure machine. Blood pressure will be monitored every 15 min for 3 hours after breakfast, lunch and dinner on each study day (from 0800h to 2100h). Gastrointestinal symptoms during the treatment period will be assessed using the validated Gastroparesis Cardinal Symptom Index Daily Diary.

At ~0900h, participants will consume a standardised mashed potato meal as their breakfast comprising 65 g powdered potato (Continental Deb instant mashed plain potato, Epping, NSW) and 20 g glucose reconstituted with 250 mL boiling water and one egg yolk containing 100 uL 13C-octanioc acid (368.5 kCal). Breath samples will be collected every 5 min in the first 30 min and every 15 min for another 210 min for the measurement of gastric emptying.

At ~1300h, participants will consume a standardised lunch and then be free to leave the laboratory.
At ~1900h, participants will consume a standardised dinner at home.

Participant will be able to choose their lunch and dinner meals from a range of frozen meal options, which will remain consistent throughout the study period (e.g. Beef Rissoles 320g, 1520kJ, On The Menu; Chicken Parmigiana 320g, 1670kJ, On The Menu; Slow Cooked Lamb 320g, 1240 kJ, On The Menu; Vegetarian options: Quorn Meat-Free Loaded Beefy Mac & Cheese 350g, 1630kJ, Kitchen Roasted Vegetable Lasagne 400g, 1670kJ). On Day 11, the CGM sensor will be removed by the investigator at CRF of the AHMS building.
Intervention code [1] 334435 0
Treatment: Drugs
Description of the comparator or control
Placebo: cellulose in gelatin capsules
Control group
Placebo

Outcomes
Primary outcome [1] 345800 0
Difference in continuous glucose monitoring (CGM)-recorded glucose levels after standardised breakfast between the two study treatments.
Timepoint [1] 345800 0
Before, 30 min, 60 min, 120 min and 180 min after the standardised breakfast on Day 4 and Day 10 of the study.
Secondary outcome [1] 463364 0
Difference in continuous glucose monitoring (CGM)-recorded glucose levels after standardised lunch between the two study treatments.
Timepoint [1] 463364 0
Before, 30 min, 60 min, 120 min and 180 min after the standardised lunch on Day 4 and Day 10 of the study.
Secondary outcome [2] 463365 0
Difference in continuous glucose monitoring (CGM)-recorded glucose levels after standardised dinner between the two study treatments.
Timepoint [2] 463365 0
Before, 30 min, 60 min, 120 min and 180 min after the standardised dinner on Day 4 and Day 10 of the study.
Secondary outcome [3] 463366 0
Difference in gastric emptying after standardised breakfast between the two study treatments.
Timepoint [3] 463366 0
Before, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 135 min, 150 min, 165 min, 180 min, 195 min, 210 min, 225 min and 240 min after the standardised breakfast.
Secondary outcome [4] 463367 0
Difference in mean amplitude of glycaemic excursions (MAGE) of continuous glucose monitoring (CGM)-recorded glucose levels between the two study treatment periods.
Timepoint [4] 463367 0
Two treatment periods (days 2-4 and days 8-10).
Secondary outcome [5] 463372 0
Difference in time in range (TIR) of continuous glucose monitoring (CGM)-recorded glucose levels between the two study treatment periods.
Timepoint [5] 463372 0
Two treatment periods (days 2-4 and days 8-10).
Secondary outcome [6] 463373 0
Difference in blood pressures between the two study treatment periods.
Timepoint [6] 463373 0
Before, 15 min, 30 min, 60 min, 90 min, 120 min and 180 min after the standardised breakfast, lunch and dinner on Day 4 and Day 10 of the study.

Eligibility
Key inclusion criteria
- Type 2 diabetes (American Diabetes Association criteria) managed by a stable dose of metformin monotherapy for more than 3 months
- Body mass index (BMI) from 20 to 40 kg/m2
- Males and females, aged from 18 to 79 years
- Glycated haemoglobin (HbA1c) from 6.0 to 8.0%
Minimum age
18 Years
Maximum age
79 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
- History of any form of heart disease or symptoms of syncope or pre-syncope (including feeling lightheaded or dizzy, feeling unsteady when standing, unexplained falls, fainting, unexplained changes in vision, such as blurring or tunnel vision)
- Use of any medication that may influence gastrointestinal motor function, body weight or appetite (opiates, anticholinergics, levodopa, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, prucalopride, or erythromycin)
- History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery (other than uncomplicated appendicectomy or cholecystectomy), or coagulation abnormalities
- Other significant illness, including epilepsy, cardiovascular or respiratory disease
- Impaired renal or liver function (as assessed by calculated creatinine clearance less than 60 mL/min or abnormal liver function tests (greater than 2 times upper limit of normal range))
- Female participants who are pregnant or planning for pregnancy, or are lactating
- Participation in any other research studies within the previous 3 months
- Inability to give informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by a computer.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
Based on data derived from the previous study (Xie et al. Diabetologia 2024;67:1260-70), 16 participants will provide more than 80% power (at a equals to 0.05) to detect at least 30% reduction in the incremental area under the curve (iAUC) for blood glucose levels after each standardised meal (as recorded by CGM), when metformin is taken 60 min before vs. with meals. 18 participants will be recruited to allow for drop-outs.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 322164 0
Charities/Societies/Foundations
Name [1] 322164 0
Australian Diabetes Society
Country [1] 322164 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 325066 0
None
Name [1] 325066 0
Address [1] 325066 0
Country [1] 325066 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320696 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 320696 0
Ethics committee country [1] 320696 0
Australia
Date submitted for ethics approval [1] 320696 0
15/05/2026
Approval date [1] 320696 0
11/06/2026
Ethics approval number [1] 320696 0
2026/HRE00207

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151314 0
A/Prof Tongzhi Wu
Address 151314 0
Level 6 AHMS Building, The University of Adelaide, North Terrace, Adelaide, SA 5000
Country 151314 0
Australia
Phone 151314 0
+61 8 8313 6535
Fax 151314 0
Email 151314 0
Contact person for public queries
Name 151315 0
Tongzhi Wu
Address 151315 0
Level 6 AHMS Building, The University of Adelaide, North Terrace, Adelaide, SA 5000
Country 151315 0
Australia
Phone 151315 0
+61 8 8313 6535
Fax 151315 0
Email 151315 0
Contact person for scientific queries
Name 151316 0
Tongzhi Wu
Address 151316 0
Level 6 AHMS Building, The University of Adelaide, North Terrace, Adelaide, SA 5000
Country 151316 0
Australia
Phone 151316 0
+61 8 8313 6535
Fax 151316 0
Email 151316 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: The ethical statement and informed consent do not allow for free data availability.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.